Dr. Mark Gerstein of Yale University speaks to CHI on January 16, 2015. Dr. Gerstein will be a speaker during the Clinical Genomics track at Bio-IT World Conference & Expo, April 21-23, 2015 in Boston, MA.
 
Topics include evolving data science applications to genomics, the utility of networks for biological data analysis and integration, studying non-coding mutations for cancer genomics and personal genomics research, the computational tool FunSeq and more.

http://www.bio-itworldexpo.com/

BioIT World 2015 | Applying Data Science, Bioinformatics and Networks to Cancer Genomics

Dr. Jennifer Chadwick shares her journey from academia to industry, and the best advice that got her to where she is today.

PEGS Boston 2019 | Jennifer Chadwick’s Story of Building a Creative and Authentic Career in Science

Dr. Mark Stewart discusses the role of the tumor mutational burden (TMB) in cancer research and the need for harmonization throughout the process.

For more information, please visit https://www.triconference.com/Companion-Diagnostics

Molecular Med Tri-Con 2019 | Target the Tumor Mutational Burden and Pursue Harmonization

Harry Glorikian interviews Niven R. Narain about his approach on how to add more precision to the process of drug development and diagnostic development while engage more reproducibility. Niven also discusses how to use the biomarkers not only as a readout but as a vehicle and an agent to design clinical trials much differently.

For more information, please visit https://www.TriConference.com/Precision-Medicine

Molecular Med Tri-Con 2019 | Real Precision Medicine is Starting with the Patient

Dr. Richard Levenson discusses the role of AI in digital pathology – what works, and what needs to be done for AI to reach its full potential.

For more information, please visit https://www.TriConference.com/Digital-Pathology

Molecular Med Tri-Con 2019 | Putting the AI in Wait

Dr. Konstantinos Mitsakakis explains the One Health approach, and how the pursuit benefits diverse avenues of diagnostic research.

For more information, please visit https://www.MolecularDXEurope.com/Point-of-Care-Dx

Molecular DX Europe 2019 | Using Point-of-Care Diagnostics to Advance a One Health Approach

Samuel Levy of Bluestar Genomics speaks to CHI on March 13, 2019. Dr. Levy will be speaking during The Liquid Biopsy Summit, June 17-19, in San Francisco, CA.
 
Topics include cell-free diagnostics in precision medicine, transformation & growth in the liquid biopsy field, epigenomic assays for cancer detection, and opportunities ahead.

For more information, please visit https://www.LiquidBiopsySummit.com/Programs

the Liquid Biopsy Summit 2019 | Reimagining Liquid Biopsy Applications with Epigenomics

Prof. Joshua Krieger from Harvard Business School shares his perspectives on some of the challenges and opportunities in commercialization of diagnostic tests and gives us a preview of his business case study on Genomic Health.

For more information, please visit https://www.NextGenerationDx.com/Commercialization-Molecular-Diagnostics

Next Generation Dx 2019 | Launch a Paradigm Shift through an Innovative Diagnostic Test

Nancy Sajjadi, an independent bioassay quality consultant with over 30 years of experience in biopharmaceutical product development, discusses her history in the bioassay field and how her experience has fostered her passion for teaching biostatistics to non-statisticians with CHI.
 
Topics include: challenges in developing bioassays for cell & gene therapies, regulatory considerations and standards for bioassays, fostering collaboration between statisticians and bench scientists, and more

For more information, please visit https://www.ImmunogenicitySummit.com/Workshop

Immunogenicity Summit 2019 | From Cell & Gene Therapy to Biostatistics

Gene therapy presents a promising path ahead for patients of rare diseases. The United States Food and Drug Administration’s Director of the Center for Biologics Evaluation and Research, Dr. Peter Marks discusses his work advancing production and availability of gene therapies for rare disorders, and the unique challenges to producing efficacious therapeutics in this field.

For more information, please visit https://www.TriConference.com/Gene-Therapy

Molecular Med TriCon 2019 | Gene Therapy for Rare Disorders

Prof. Matthew Lungren shares his stories on how he got to where he is now and where his artificial intelligent inspiration for medicine comes from. He also talks about many great collaborations at the Stanford Center in precision medicine and what he’s looking to see more in this field in the next 5 years. 

For more information, please visit https://www.TriConference.com/Precision-Medicine

Molecular Med Tri-Con 2020 | Artificial Intelligence in Precision Medicine

The CHI Podcasts are produced by the Cambridge Healthtech Institute and offer in-depth interviews with research and business leaders from many facets of biotechnology.